Indegene Limited has announced a scheduled investor/analyst meeting as part of its regulatory compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The pharmaceutical services company informed both BSE and NSE about the upcoming engagement through an official communication dated March 13, 2026.

Meeting Details

The company has scheduled a focused investor interaction for March 18, 2026, with specific details outlined for stakeholder transparency.

Regulatory Compliance

The meeting notification follows standard regulatory protocols under SEBI guidelines. Company Secretary and Compliance Officer Srishti Ramesh Kaushik signed the official communication, emphasizing the company's commitment to transparency and regulatory adherence.

Key compliance aspects include:

• No unpublished price sensitive information will be shared during the meeting
• Meeting details made available on the company website at www.indogene.com
• Schedule subject to change due to exigencies
• Proper notification to both stock exchanges

Company Information

Indegene Limited operates from its headquarters at Manyata Embassy Business Park in Bengaluru, Karnataka. The company maintains its listing on both major Indian stock exchanges with scrip code 544172 on BSE and trading symbol INDGN on NSE. The formal communication ensures all stakeholders remain informed about the company's investor engagement activities as required under current listing regulations.

Indegene Limited has announced the acquisition of two UK-based healthcare consulting companies through its wholly owned subsidiary, Indegene Healthcare UK Limited. The company signed a Share Purchase Agreement on March 01, 2026, to acquire 100% equity shares in DT Associates Research and Consulting Services Limited and Trilogy Writing and Consulting Limited, both based in London.

Acquisition Details

The strategic acquisition involves two target companies operating in the healthcare consulting space:

Target Company Profiles

DT Associates Research and Consulting Services Limited provides comprehensive solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. The company was incorporated and registered in England and Wales and reported revenue of GBP 6,400,711 in its last financial year.

Trilogy Writing and Consulting Limited specializes in providing writing and training services for the pharmaceutical industry. Also incorporated and registered in England and Wales, the company reported revenue of GBP 2,340,488 in its last financial year.

Financial Performance History

Both companies have demonstrated consistent revenue generation over the past three years:

DT Associates Three-Year Revenue:

Trilogy Writing Three-Year Revenue:

Transaction Structure

The acquisition is structured as an internal restructuring initiative within the Indegene group. Following completion, both DT Associates and Trilogy Writing will cease to be subsidiaries of their current parent companies and will become wholly owned subsidiaries of Indegene Healthcare UK Limited.

The transaction falls within related party transactions and is being conducted on an arm's length basis. Both acquisitions strengthen Indegene's presence in the UK healthcare consulting market and complement the company's existing service offerings in life sciences and pharmaceutical sectors.